Is XYL a good stock to buy?
Xylem Inc. · end-of-day data as of Nov 13, 2026
- PT$124.00 +31.7%
- ConsensusBuy · 22
- P/E vs own-27.5%
- P/E vs sector-23.9%
- FCF yield+4.3%
- Insiders$986K
- News
- Earnings in88d
- P/E20.8x
- RSI40
- Resistance+7.2%
- Off 52w high-35.8%
- Volume0.5x
- Bollingerlower half
- Trendsideways
- 52w range$87–$147
- ATR+3.4%
- Off ATH-39.0%
- MAs0 of 4
- MACD-0.15
- Sector▼ -11.7%
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Xylem a good stock to buy?
Xylem is strong on 3 of the 5 questions about the business. The price is low: 20.8 times its earnings, below its 3-year median of 34.2 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand growing
- Advantage some edge
- Economics profitable
- Execution delivers
- Fragility sturdy
- Price below its usual
XYL sales growth revenue growth
+18%a year, for the last 3 yearsXylem's sales grew 18% a year for 3 years, to $9.04B in fiscal 2025.
XYL analysts' forecast revenue estimates
-1%the sales they expect next fiscal year, on the lastAnalysts expect Xylem's sales to fall 1% to $8.97B in fiscal 2026 (13 analysts).
XYL return on capital ROIC
pretickt analysis11%earned before tax on the money invested in itXylem earned 11% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Nordson 16%, Dover 16% and IDEX 15%.
XYL margin on each sale gross margin
40%left after making the productXylem kept 40% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 42%.
XYL margin after costs profit margin
15%of sales left after running the businessXylem's operating margin was 15% in the 12 months to Sep 30, 2026, against 11% in fiscal 2022.
XYL cash generated free cash flow
$921Mcash left after investing, last 12 monthsXylem generated $921M of free cash flow in the 12 months to Sep 30, 2026, less than its reported profit.
XYL earnings vs estimates
7 of 8quarters above the analysts' estimateXylem beat the analysts' profit estimate in 7 of its last 8 quarters, the latest on Oct 27, 2026.
XYL insider buying
+$625Kbought, net, by its executives in 12 monthsXylem's executives and directors bought a net $625K of shares in the 12 months to Nov 13, 2026 ($1.13M bought, $501K sold).
XYL number of employees
-4%fewer people in a yearXylem had 22,000 employees at the end of fiscal 2025, 4% fewer than a year before.
XYL CEO pay
$10.83Mfor fiscal 2023, 64% of it in stock and optionsXylem paid its CEO $10.83M for fiscal 2023, 64% of it in stock and options.
XYL financial health Altman Z-score
3.1Altman Z-score, safe above 3Xylem's Altman Z-score is 3.1 (Nov 13, 2026), above 3, where the safe zone starts.
XYL quality checks Piotroski score
7 of 9checks passedXylem passes 7 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on long-term debt and the current ratio.
XYL biggest customers
under 10%of sales from any one customerNo customer made 10% of Xylem's sales in fiscal 2025.
XYL price vs profit P/E ratio
20.8×a year's earningsXylem's P/E ratio is 20.8 (Nov 13, 2026), below its 3-year median of 34.2.
XYL price vs competitors
pretickt analysis20.8×a year's earnings, against its competitorsInvestors pay 20.8 times Xylem's earnings (Nov 13, 2026), less than for Symbotic (376.1), IDEX (33.0), Nordson (32.8) or Dover (24.5).
XYL analysts' target price target
+32%to their average targetAnalysts' average price target for Xylem is $124, 32% above the Nov 13, 2026 close of $94.18.
XYL analyst ratings, 90 days
pretickt analysisJP Morgandowngrade Barclaysdowngrade Argus Researchdowngrade
In the 90 days to Nov 13, 2026, JP Morgan, Barclays and Argus Research downgraded Xylem.
XYL growth priced in fair value
pretickt analysis+9%a year, for ten years, to be worth the priceAt $94.18 a share, Xylem's free cash flow must grow about 9% a year for ten years to be worth the price (Nov 13, 2026).
What is Xylem's P/E ratio?
Xylem's P/E ratio is 20.8 (Nov 13, 2026), below its 3-year median of 34.2. Investors pay 20.8 times Xylem's earnings (Nov 13, 2026), less than for Symbotic (376.1), IDEX (33.0), Nordson (32.8) or Dover (24.5).
Who are Xylem's biggest competitors?
pretickt compares Xylem with Symbotic, Nordson, IDEX and Dover. Xylem's sales grew 2% in the 12 months to Sep 30, 2026, slower than Symbotic (+21%), Dover (+8%), Nordson (+7%) and IDEX (+7%).
Is Xylem profitable?
Xylem's operating margin was 15% in the 12 months to Sep 30, 2026, against 11% in fiscal 2022. Xylem generated $921M of free cash flow in the 12 months to Sep 30, 2026, less than its reported profit.
Are insiders buying Xylem stock?
Xylem's executives and directors bought a net $625K of shares in the 12 months to Nov 13, 2026 ($1.13M bought, $501K sold).
How many employees does Xylem have?
Xylem had 22,000 employees at the end of fiscal 2025, 4% fewer than a year before.
Who are Xylem's biggest customers?
No customer made 10% of Xylem's sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.